233 related articles for article (PubMed ID: 31694585)
1. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
2. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
3. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
5. Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Park JH; Szemes M; Vieira GC; Melegh Z; Malik S; Heesom KJ; Von Wallwitz-Freitas L; Greenhough A; Brown KW; Zheng YG; Catchpoole D; Deery MJ; Malik K
Mol Oncol; 2015 Mar; 9(3):617-27. PubMed ID: 25475372
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
7. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PRMT5 Attenuates Oxidative Stress-Induced Pyroptosis via Activation of the Nrf2/HO-1 Signal Pathway in a Mouse Model of Renal Ischemia-Reperfusion Injury.
Diao C; Chen Z; Qiu T; Liu H; Yang Y; Liu X; Wu J; Wang L
Oxid Med Cell Longev; 2019; 2019():2345658. PubMed ID: 31885778
[TBL] [Abstract][Full Text] [Related]
9. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
[TBL] [Abstract][Full Text] [Related]
10. Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.
Mongiardi MP; Savino M; Bartoli L; Beji S; Nanni S; Scagnoli F; Falchetti ML; Favia A; Farsetti A; Levi A; Nasi S; Illi B
Sci Rep; 2015 Nov; 5():15494. PubMed ID: 26563484
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
12. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.
Liu M; Yao B; Gui T; Guo C; Wu X; Li J; Ma L; Deng Y; Xu P; Wang Y; Yang D; Li Q; Zeng X; Li X; Hu R; Ge J; Yu Z; Chen Y; Chen B; Ju J; Zhao Q
Theranostics; 2020; 10(10):4437-4452. PubMed ID: 32292506
[TBL] [Abstract][Full Text] [Related]
13. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
[TBL] [Abstract][Full Text] [Related]
14. EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
Liu X; He J; Mao L; Zhang Y; Cui W; Duan S; Jiang A; Gao Y; Sang Y; Huang G
Exp Eye Res; 2021 Jan; 202():108286. PubMed ID: 33035554
[TBL] [Abstract][Full Text] [Related]
15. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
[TBL] [Abstract][Full Text] [Related]
16. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Karkhanis V; Alinari L; Ozer HG; Chung J; Zhang X; Sif S; Baiocchi RA
J Biol Chem; 2020 Jan; 295(5):1165-1180. PubMed ID: 31822509
[TBL] [Abstract][Full Text] [Related]
17. The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells.
Favia A; Salvatori L; Nanni S; Iwamoto-Stohl LK; Valente S; Mai A; Scagnoli F; Fontanella RA; Totta P; Nasi S; Illi B
Sci Rep; 2019 Nov; 9(1):15925. PubMed ID: 31685892
[TBL] [Abstract][Full Text] [Related]
18. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
19.
Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
[TBL] [Abstract][Full Text] [Related]
20. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
